171 results about "Type II collagen" patented technology

Methods and devices for the regulation of type II collagen gene expression in cartilage cells via the application of specific and selective fields generated by specific and selective electric and electromagnetic signals in the treatment of diseased or injured articular cartilage. By gene expression is meant the up regulation or down regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased cartilage tissue that include generating specific and selective electric and electromagnetic signals that generate specific and selective fields optimized for type II collagen gene expression and exposing cartilage tissue to the specific and selective fields generated by specific and selective signals so as to regulate type II collagen gene expression in such cartilage tissue. The resulting methods and devices are useful for the targeted treatment of osteoarthritis, rheumatoid arthritis, cartilage injury, and cartilage defects.

The integral engineering rack of interface osteochondro tissue with bionic interface includes from the top to the bottom one cartilage layer, one calcified layer and one bone layer below cartilage connected organically. The cartilage layer consists of type II collagen and chitosan connected in covalent bond; the calcified layer consists of type II collagen and hydroxyapatite connected in covalent bond; the bone layer below cartilage consists of type I collagen and hydroxyapatite connected in covalent bond; and each of the cartilage layer and the bone layer below cartilage has at least one pore of 100-500 micron size. The integral engineering rack of the present invention has excellent biocompatibility, excellent degradability, sufficient mechanical first and bionic interface function.

The present application discloses compositions, methods and devices for treatment of a degenerative intervertebral disc. A composition can comprise chondrocytes expressing type II collagen. These chondrocytes can be obtained from human cadavers up to about two weeks following death, and can be grown in vitro. The compositions can further comprise one or more biocompatible molecules. Treatment of a degenerative disc can comprise injecting or implanting a composition comprising the chondrocytes into a degenerative disc.

The invention discloses a novel chondrocyte epimatrix membrane and a preparation method thereof. The membrane contains cell epimatrix ingredients which have bioactivity and cell activity, wherein the cell epimatrix comprises the following main ingredients in percentage by weight: 80 to 95 percent of bionic type II collagen in an acellular cartilage matrix and 10 to 20 percent of hyaluronic acid, 10 to 20 percent of aminopolysaccharide and the like which serve as a chondrocyte epimatrix; the chondrocyte epimatrix biological membrane prepared from the acellular cartilage matrix has the bionic chondrocyte epimatrix ingredients, is excellent in cell consistency, does not arouse immunological rejection of host cartilage tissue, can be used for repairing the damage of hyaline cartilage tissue of joints and reconstructing the hyaline cartilage tissue, and also can be used for a seed cell inoculating vector and a growth factor sustained-release vector; and the chondrocyte epimatrix contains blood vessel inhibiting factor ingredients, so the membrane also can be used for preventing the conglutination of tissue such as muscle tendons.

The present invention relates to compositions for the modulation of inflammation in connective tissues in humans and animals and the modulation of markers of such inflammation, including COX-2, TNF-α, IL-1β, iNOS, p38, and chemokines, comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothioneine, methylsulfanylmethane, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.

The invention discloses a bone implant and a manufacturing method thereof. The manufacturing method of the bone implant comprises a step of coating or mixing type II collagen with at least one porous bone material comprising metals, bio-ceramics, natural biopolymers and synthetic polymers. Another manufacturing method of the bone implant comprises the steps of loading type II collagen with or without at least one porous bone material in a container, and lyophilizing the type II collagen to generate a type II collagen sponge construct with or without the porous bone material as the bone material. The manufactured bone implants are effective, with or without loading cells having differentiation tendency towards osteogenesis, to facilitate bone repair upon introduction of the bone implant into various osseous defects.

The invention provides a preparation method of cartilage extract containing non-denatured type II collagen. The method comprises the following steps: degreasing, disinfecting, homogenizing, enzymatic hydrolysis, filtration and drying. In the enzymatic hydrolysis step, the pH of a slurry obtained in the homogenizing step is adjusted to 2.5-8.5, an enzyme accounting for 0.001-2%of the weight of cartilages is added, a clear liquid accounting for 1/20 to 1/500 of the weight of the cartilages and obtained through juicing pawpaw and/or pineapples and filtering the obtained juice is added, the enzymatic hydrolysis is carried out at 25-50 DEG C for 12-48 h, and the enzyme is preferably selected from one or more of pepsin, subtilisin, alkaline proteases and metalloproteases. The cartilage extract obtained through the preparation method has the advantages of high purity, high extraction rate, and easiness in large-scale production, and richness in non-denatured type II collagen and chondroitin sulfate.

A method for separation the collagen from the various animal tissues is disclosed for preparing collagen solution and product using the same. The porcine tissues are processed to have proper form and size for acid-treatment. The acid-treatment is repeated with pepsin to separate type I or II collagens. The separated collagen is salt-treated for fractionation and ethanol-treated for obtaining 5˜10% of collagen from the initial tissue weight. The prepared tissues are processed for separating collagen through the collagen separating process. The separated collagen is processed for preparing product. The method for preparing product is comprised: treating a collagen solution having a predetermined concentration under a neutral condition at a low temperature, followed by overnight treatment at a temperature of 30 to 35° C.; concentrating collagen by centrifugation; and dissolving the thus-concentrated collagen in refrigerated weakly-acidic solvent or phosphate buffered saline (PBS), thereby preparing collagen having a concentration of 1 to 5 mg/mL.

The invention provides a tissue engineered bone-cartilage composite tissue transplant and a preparation method thereof, and belongs to the tissue engineering field. The method comprises the following steps: seed cells are implanted on a scaffold material and cultured in vitro to form the tissue engineered bone-cartilage composite tissue transplant; the seed cells are osteogenic stem cells; the scaffold material comprises an osteogenic part and a chondroblast part, and the osteogenic part is added with an osteoblast induction factor and modified by a type-I collagen in a preparation process; and the chondroblast part is added with a chondroblast induction factor and modified by a type-II collagen. Bone marrow mesenchymal stem cells are successfully induced into osteocytes and chondrocytes, and bone tissues and cartilage tissues are formed after the obtained transplant is transplanted in vivo. Satisfactory effect is obtained from the tissue engineered bone-cartilage composite tissue which is constructed by the transplant.

The invention discloses a method for producing a recombinant human type II collagen single chain by Pichia pastoris. The present invention provides a nucleotide sequence encoding the recombinant humantype II collagen single chain, the nucleotide sequence is shown as SEQ ID NO. 1, and a nucleotide sequence of the recombinant human type II collagen single chain coded by the nucleotide sequence SEQID NO. 1 is shown as SEQ ID NO.2. The recombinant human type II collagen single chain obtained according to the present invention comprises a full-length amino acid sequence of a mature human type IIcollagen alpha1 chain, which can effectively support the realization of the biological function of the type II collagen, and has good biological activity, an amino terminal and a carboxy terminal contain different affinity purification tags, which can realize effective purifying to obtain the full-length single-chain protein, and is also beneficial for the identification of collagen; and accordingto the expression characteristics of Pichia pastoris, the method systematically optimizes the gene sequence encoding the recombinant human type II collagen single chain, so that better expression inPichia pastoris is realized.

A method and composition are provided for inducing or enhancing chondrogenesis in vivo or in vitro. The method is performed by exposing the cells in vitro or in vivo to an extracellular matrix comprising of type I collagen, type II collagen or a mixture of type I collagen or type II collagen and hyaluronate and further containing BMP-4 or a combination of BMP-4 and GDF-5.

The invention discloses elastic protein peptide powder. The key points of the technical scheme are characterized in that the elastic protein peptide powder is prepared from the following components inparts by weight: 2,300-2,700 parts of fish collagen hydrolysate, 600-800 parts of blueberry juice powder, 600-800 parts of grape powder, 230-270 parts of cranberry juice powder, 50-350 parts of xylitol, 90-130 parts of green plum powder, 80-120 parts of acerola cherry fruit powder, 40-80 parts of type II collagen peptide hydrolysate, 80-120 parts of L-calcium lactate, 30-70 parts of soybean peptide, 8-14 parts of skipjack elastic protein peptide, 2-5 parts of blood orange powder, 10-14 parts of cubilose peptide, 80-120 parts of beet juice powder, 60-80 parts of citric acid and 1-5 parts of sucralose. The invention aims at providing the elastic protein peptide powder which can remarkably improve skin ageing.

PCT No. PCT/JP96/01623 Sec. 371 Date May 18, 1998 Sec. 102(e) Date May 18, 1998 PCT Filed Jun. 13, 1996 PCT Pub. No. WO96/41644 PCT Pub. Date Dec. 27, 1996Oral drugs and functional foods of the present invention contain type-II collagen denatured (fragmented) under specific conditions. Rheumatoid arthritis (RA) has been considered to be an autoimmune disease against type-II collagen as an antigen. Since denatured type-II collagen of the invention induces high oral immune tolerance and inhibits immune responses against type-II collagen, it can prevent and treat RA. Particularly, RA can effectively be prevented and treated by simple oral administration of type-II collagen.

The present invention relates to a method of treating exercise-induced joint pain in arthritis-free mammals by the administration of undenatured Type II collagen.

The invention discloses a method for extracting pure type II collagen from chicken cartilage. The method is characterized by including, using the fresh chicken cartilage as raw material, removing other non-cartilage components, performing degreasing pretreatment, using mixed solution of 4mol/L NaCl and 0.05mol/L Tris-HCl to remove soluble impure protein, using mixed solution (pH 7.5) of 4mol/L guanidine hydrochloride and 0.05mol/L Tris-HCl to remove insoluble impure protein, using acetic acid solution containing 1-2% pepsin for solid matter enzymolysis, then centrifuging to take supernate, adding NaCl until final concentration is 3-4.2mol/L, 1.2-1.8mol/L and 0.8-1.0mol/L, successively salting out to remove other types of collagen, repeatedly adding NaCl until the final concentration is 0.8-1.0mol/L, salting out for 2-5 times, and dialyzing to obtain the pure type II collagen. The type II collagen produced by the method is single in type, high in bioactivity, stable in physical and chemical property. Meanwhile, the method is simple to operate and capable of benefiting large-scale production.

The invention discloses a method for making medical II collagen, which is characterized in: doing pre-treatment by using fresh articular cartilage as raw material; then using hydrochloric acid carbamidine to extract proteoglycan which comprises preparing a 4M hydrochloric acid carbamidine solution, and regulating the pH value to between 6.5 and 7.5 with alkali, then pouring the Hydrochloric acid carbamidine solution which is 8 to 15 times of the articular cartilage plasma into the cartilage plasma and blend, placing the solution on the shaking bed, shaking for one or two days, centrifuging and obtaining a solid matter, removing residue hydrochloric acid carbamidine solution by ultra-pure water washing for several times; pepsin digestion, which comprises that 2000 to 5000 portions of 0.5 to 0.6M acetic acid solution is added in the solid matter, then 0.1 to 0.3 portions of 2000 to 5000 mass percent solid matter which is pepsin is added in twice , for the first time half of the total amount is added and shaken in the shaking bed for 24 hours ,for the second time the other half is added and shaken for 24 hours, centrifuged, and the supernatant is removed, added in 0.01 to 0.02M aqueous solution of EDTA and 1 to 4 inactivate pepsin; salted out with NaCl; dialyzed with Na2 HPO4 solution, then medical-grade II Collagen is obtained.

The invention discloses an arthralgia relief composition, an arthralgia relief health-care product, and application of the arthralgia relief composition. The arthralgia relief composition comprises D-glucosamine sulfate potassium chloride, calcium carbonate, chondroitin sulfate, type II collagen, non-denatured type II collagen, turmeric extract, vitamin K2 powder, and vitamin D3 powder. Human feeding trials prove that the components are synergistic, allowing arthralgia to be relieved shortly, promoting joint activity improvement, and preventing further degenerative changes in articular cartilages; the arthralgia relief composition has good safety and effect, and a quick, effective scheme is provided for relief of osteoarthritis or rheumatoid arthritis pains.

The adipose-derived stem cells are derived to express bone morphogenetic protein (BMP-4) or transforming growth factor (TCF-beta3) through a gene transduction technology. The performance-enhanced stem cell has high multiplication capacity and cartilage repair capacity and is a good tool for repairing cartilage injury. Considering the functions of the BMP-4 and TCF-beta3 on stem cell regulation and nutrition, the trophic factors are fully expressed by the stem cells through a virus vector transduction method, the capacity of culturing the improved adipose-derived stem cells and cartilage cells in a cartilage induction medium for differentiating into cartilage cells is higher than that of the common adipose-derived stem cells, more type II collagens are generated, and the formed cartilage sphere is large and dense; and meanwhile, the survival cycle of the transplanted stem cells in vivo is prolonged, the repair function of the growth factors and trophic factors on the damaged part is prolonged, and cartilage growth and wound healing are promoted.

The invention belongs to the technical field of preparation of functional polypeptide, and particularly relates to a preparation method of sturgeon bone II-type collagen peptide. The preparation method sequentially comprises the following steps: preparing sturgeon bone II-type collagen, preparing sturgeon bone II-type collagen peptide, desalting, concentrating, separating and purifying. The finally prepared II collagen peptide is low-molecular weight sturgeon cartilage II collagen peptide, and has the hydrolysis degree of 9-17% and peptide chain length range of 3-24 amino acids. The collagen peptide prepared by the preparation method is further rich in chondroitin and calcium, and has a good joint health-caring function; and in addition, the preparation method is suitable for industrial production.

The invention provides a method for inducing mesenchymal stem cells (MSCs) into chondrocytes. The method comprises the following steps of: obtaining MSCs and the chondrocytes; inoculating the chondrocytes into a chondrocyte culture solution to be cultured; inoculating MSCs in an inserted cell culture dish, placing the inserted cell culture dish in the chondrocyte culture solution again, and replacing the chondrocyte culture solution into a chondrocyte induced differentiation culture medium for co-culture. By adopting the induction method, MSCs and the chondrocytes can simulate an in-vivo environment to produce a synergy, so that induced MSCs are differentiated into chondrocyte factors to play a role of a synergistic effect for inducing factors with an extracellular matrix secreted by the chondrocytes, so as to obviously shorten the time for inducing MSCs to differentiate into chondrocytes, improve the proliferation rate of the chondrocytes, and simultaneously enhance the expression rate and the expression quantity of type II collagens which induce the differentiated cells and the secretion of glycosaminoglycan (GAG).

The invention relates to a preparation method for an I/II type double-layer composite collagen membrane and the I/II type double-layer composite collagen membrane prepared by using the preparation method. The preparation method comprises the following steps: 1, extracting type-I collagen and preparing a type-I collagen membrane; 2, extracting type-II collagen and preparing a type-II collagen membrane; and 3, with the type-I collagen membrane as a bottom layer and the type-II collagen membrane as a top layer, carrying out crosslinking so as to form the I/II type double-layer composite collagen membrane. The I/II type double-layer composite collagen membrane provides a good growth environment for chondrocytes and has a good cartilage repair effect.